The COMPASSION‑16 Phase III trial reported that adding cadonilimab to first‑line chemotherapy—alone or with bevacizumab—improved outcomes in advanced cervical cancer. Trial investigators presented efficacy and safety findings indicating the PD‑1/CTLA‑4 bispecific antibody enhanced response rates compared with chemotherapy alone, suggesting a new immunotherapy option for a disease with limited first‑line systemic choices. The data were positioned as practice‑changing for regions where cervical cancer remains a major cause of mortality; sponsors and investigators plan regulatory discussions and potential label filings. The trial’s readout also spotlights cadonilimab as a commercial and partnering asset in oncology, with implications for competitor pipelines targeting similar indications.